Cancer Reports (Aug 2022)

Catecholamines in neuroblastoma: Driver of hypertension, or solely a marker of disease?

  • Matthew Harding,
  • Rebecca J. Deyell,
  • Tom Blydt‐Hansen

DOI
https://doi.org/10.1002/cnr2.1569
Journal volume & issue
Vol. 5, no. 8
pp. n/a – n/a

Abstract

Read online

Abstract Background Neuroblastoma is a common solid tumor of childhood and is often associated with hypertension. Potential etiologies contributing to hypertension include renal compression, pain, volume overload, and catecholamine secretion. Cases We completed a single center retrospective review of children with neuroblastoma and ≥stage II hypertension (per Hypertension Canada guidelines) over a 2‐year period. All patients (n = 10) had elevated urine normetanephrine levels and eight had intra‐abdominal tumors. Four patients had refractory hypertension requiring > three agents, of which three required alpha/beta blockade. Conclusion Although multifactorial, hypertension in neuroblastoma often has a neuroendocrine component. Excess normetanephrine production in neuroblastoma may be a more common hypertensive mechanism than previously appreciated. Urinary normetanephrine elevation could suggest potential neuroendocrine‐mediated hypertension.

Keywords